A Prospective, Open-Label, Randomized, Comparative, Investigator-Initiated Study to Evaluate the Safety and Effectiveness of Autologous Growth Factor Concentrate Using the Healrex Therapy Kit With Standard Wound Care in Lower-Extremity Diabetic Ulcer.

Background and objectives The persistent nature of diabetic foot ulcers (DFUs) is mainly attributable to compromised wound healing mechanisms, which are aggravated due to poor blood flow, neuropathy, and infection. Growth factors have become essential agents in the treatment of DFUs, serving as primary mediators that enhance wound healing through the stimulation of cell proliferation, migration, and angiogenesis. This prospective open-label, randomised, comparative, multi-centre, investigator-initiated study compared the safety and effectiveness of adjuvant therapy with topical application of autologous growth factor concentrate (AGFC) using the Healrex therapy kit (Wockhardt, India) versus standard of care (SoC) in DFUs.

Water insecurity is associated with sugar-sweetened beverage consumption in a small-scale population in Lowland Bolivia experiencing lifestyle changes.

Background: Emerging evidence indicates water insecurity (WI) is detrimental to nutritional outcomes and dietary choices.

Objective: This study measured WI experiences alongside market and traditional sugar-sweetened beverage (SSB) consumption in a small-scale society experiencing early stages of the nutrition transition (i.e.

Racial disparities in timing and outcomes for patients undergoing staged single ventricle palliation: a single institution report.

Background: Racial disparities in healthcare have been well documented in the United States. We hypothesise that there will be a racial variance in different clinical variables in single-ventricle patients through stages of palliation.

Materials And Methods: Retrospective single-centre study stratified all single-ventricle patients who reached stage 2 palliation by race: Black and White.

Anticoagulation in patients with a history of heparin-induced thrombocytopenia who require cardiovascular surgery: is it okay to use heparin?

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction with significant thromboembolic risk. Though there are models for use of non-heparin anticoagulants, heparin remains the preferred anticoagulant in many operative settings, especially cardiovascular surgery and percutaneous cardiac intervention. The natural history of HIT can be stereotyped into phases using HIT laboratory testing to guide clinical management and determine whether heparin re-exposure can be considered.